Abstracts tagged "Pediatric rheumatology"

Abstract Number: 2677 • ACR Convergence 2025
Quantified Imaging Response at the Sacroiliac Joints to TNF-Inhibitor Therapy in Youth with Axial Disease
Timothy Brandon¹, Rui Xiao², Daniel Lovell³, Edward Oberle⁴, Matthew Stoll⁵, Nancy A. Chauvin⁶, Michael Francavilla⁷, Walter P. Maksymowych⁸ and Pamela Weiss⁹, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Nationwide Children's Hospital, Columbus, OH, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶The Cleveland Clinic, Hummelstown, PA, ⁷Department of Pediatric Radiology, Children’s Hospital Philadelphia, Philadelphia, PA, ⁸Department of Medicine, University of Alberta, ⁵⁶⁸ Heritage Building, Edmonton, AB, Canada, ⁹Childrens Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: This study assessed the timeline for the resolution of inflammation, changes in structural lesions at the sacroiliac joints (SIJ), and their correlation with patient-reported…
Abstract Number: 2156 • ACR Convergence 2025
Bridging the Gap: Juvenile Spondyloarthritis (JSpA) vs. Chronic Non-Bacterial Osteomyelitis (CNO)
Sophia Elfrink¹, Timothy Brandon¹, Jahan Jazayeri¹ and Pamela Weiss², ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²Childrens Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: The relationship between juvenile spondyloarthritis (JSpA) and chronic nonbacterial osteomyelitis (CNO) remains poorly defined. This study aimed to assess the proportion of pediatric patients…
Abstract Number: 2132 • ACR Convergence 2025
The Bridge to Adult Care from Childhood for Young Adults with Rheumatic Disease (BACC YARD) Program, a Pediatric-To-Adult Rheumatology Transition Program, Reduces Median Time between Final Pediatric, First Adult, and Second Adult Visits
Ayah Eltoum¹, Eileen Rife², Livie Timmerman³, Emily Smitherman⁴, Melissa Mannion⁴ and John Bridges⁵, ¹University of Alabama at Birmingham, Hoover, AL, ²University of Alabama Birmingham, Vestavia Hills, AL, ³University of Alabama at Birmingham, Gardendale, AL, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵University of Alabama at Birmingham/Children's of Alabama, Birmingham, AL
Background/Purpose: The transition from pediatric to adult-oriented rheumatology care is a critical period for young adults with childhood-onset rheumatic diseases. The Bridge to Adult Care…
Abstract Number: 1818 • ACR Convergence 2025
Epigenetic Profiling of Childhood-onset Lupus Reveals Distinct Epigenetic Clusters and Suggests Epigenetic Drivers of Disease Activity
Desire Casares Marfil¹, Gülşah Kavrul Kayaalp², Vafa Guliyeva², Özlem Akgün², Şeyma Türkmen³, Elif Kilic Konte⁴, Seher Şener⁵, Sezgin Sahin⁴, Ozgur Kasapcopur⁶, Betul Sozeri⁷, Selçuk Sözer Tokdemir⁸, Seza Özen⁹, Nuray Aktay Ayaz² and Amr Sawalha¹, ¹University of Pittsburgh, Pittsburgh, PA, ²Istanbul University Faculty of Medicine, Istanbul, Turkey, ³University of Health Sciences, Umraniye Research and Training Hospital, Istanbul, Turkey, ⁴Istanbul University Cerrahpasa Medical School, Istanbul, Turkey, ⁵Hacettepe University Faculty of Medicine, Ankara, Turkey, ⁶Istanbul University-Cerrahpasa, Cerrahpasa Medical School, istanbul, Turkey, ⁷Health sciences university, Istanbul, Turkey, ⁸Istanbul University, Istanbul, Turkey, ⁹Hacettepe University Medical Faculty, Ankara, Turkey
Background/Purpose: Childhood-onset lupus is generally associated with a more severe disease course than adult-onset lupus. DNA methylation alterations are known to play a key role…
Abstract Number: 1691 • ACR Convergence 2025
Standardizing DXA Screening in Childhood-Onset Systemic Lupus Erythematosus at A Single Center: A Quality Improvement Initiative Using a Decision-Tree Algorithm
Andrea Gutierrez¹, Stephanie Armendariz², Muniza Mogri³ and Kristina Ciaglia⁴, ¹UT Southwestern Medical Center, Dallas, TX, ²Texas Scottish Rite Hospital, Dallas, TX, ³UT Southwestern Medical Center / Children’s Health Dallas, Dallas, TX, ⁴UT Southwestern, Children's Medical Center, and Scottish Rite for Children, Dallas, TX
Background/Purpose: Patients with childhood-onset systemic lupus erythematosus (cSLE) are at increased risk of low bone mineral density, with studies showing a 40% frequency of osteopenia (Lilleby,…
Abstract Number: 1295 • ACR Convergence 2025
Neuropsychiatric Lupus in Children and Adolescents: Understanding Current Practices and Barriers to Care Perceived by Pediatric Rheumatology Clinicians in North America
Martha Rodriguez¹, Ekemini Ogbu², Ashley Danguecan³, Marietta De Guzman⁴, Alexandra Theisen⁵, Lawrence Ng⁶, Andrea Knight³ and Ryann Kammeyer⁷, ¹Riley Hospital For Children at Indiana University, Indianapolis, IN, ²Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Hospital for Sick Children, Toronto, ON, Canada, ⁴Baylor College of Medicine, Houston, TX, ⁵University of Arkansas, Little Rock, AR, ⁶The Hospital for Sick Children, Toronto, Canada, Toronto, ON, Canada, ⁷University of Colorado, Denver, CO
Background/Purpose: Neuropsychiatric involvement in Systemic Lupus Erythematosus (NPSLE) is a major cause of morbidity and mortality, particularly among children who are still developing neurologically. Despite…
Abstract Number: 1279 • ACR Convergence 2025
Whole Blood Gene Expression Defined Subgroups of Treatment Naïve Children and Adolescents with Childhood-onset Systemic Lupus Erythematosus.
Reagan Reid¹, Huayun Hou², Isha Datar², Daniela Dominguez³, Andrea Knight⁴, Deborah Levy⁵, Lawrence Ng⁶, Zhaoyu Ding², Michael Wilson², Lauren Erdman⁷, Eleanor Pullenayegum² and Linda Hiraki⁵, ¹The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ²SickKids Research Institute, Toronto, ON, Canada, ³The Hospital for Sick Children, Toronto, Canada, ⁴Hospital for Sick Children, Toronto, ON, Canada, ⁵The Hospital for Sick Children, Toronto, ON, Canada, ⁶The Hospital for Sick Children, Toronto, Canada, Toronto, ON, Canada, ⁷University of Cincinnati, Cincinnati, OH
Background/Purpose: Childhood-onset systemic lupus erythematosus (cSLE) is a clinically and genetically heterogeneous disease. We aimed to define subgroups of new diagnosis patients based on treatment…
Abstract Number: 0820 • ACR Convergence 2025
Novel Autoantibodies Predictive of Atherosclerosis Progression and Statin Response in Juvenile-Onset Systemic Lupus Erythematosus
Junjie Peng¹, Pierre Donnes¹, Thomas McDonnell¹, Laura Schanberg², Stacy Ardoin³, Laura Lewandowski⁴, George Robinson¹, Elizabeth C Jury¹ and Coziana Ciurtin¹, ¹University College London, London, United Kingdom, ²Duke University Medical Center, DURHAM, NC, ³Nationwide Children's Hospital, Columbus, OH, ⁴NIAMS, NIH, Bethesda, MD
Background/Purpose: Cardiovascular disease (CVD) is a leading cause of morbidity and mortality in juvenile-onset systemic lupus erythematosus (JSLE). There is an urgent need to identify…
Abstract Number: 0403 • ACR Convergence 2025
IL-6 as a Predictor of Response to Olokizumab in Polyarticular-Course Juvenile Idiopathic Arthritis: Results of the Phase 2 Clinical Trial
Ekaterina Alexeeva¹, Tatiana Dvoryakovskaya¹, Elena Zholobova², Elizaveta Krekhova³, Valeria Matkava⁴, Rinat Raupov⁵, Daria Bukhanova⁶, Alina Egorova⁶, Sergey Grishin⁶, Mikhail Samsonov⁶, Mikhail Kostik⁷ and Irina Nikishina⁴, ¹National Medical Research Center for Children’s Health Federal State Autonomous Institution of the Russian Federation Ministry of Health and I.M. Sechenov First Moscow State Medical University (Sechenovskiy University), Moscow, Russia, ²I.M.Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia, ³National Medical Research Center for Children’s Health Federal State Autonomous Institution of the Russian Federation Ministry of Health, Moscow, Russia, ⁴V.A.Nasonova Research Institute of Rheumatology, Moscow, Russia, ⁵H.Turner National Medical Research Center for Childrens Orthopaedics and Trauma Surgery, Saint-Petersburg, Russia, ⁶R-Pharm JSC, Moscow, Russia, ⁷Saint-Petersburg State Pediatric Medical University, Saint Petersburg, Russia
Background/Purpose: Olokizumab (OKZ) is a direct interleukin-6 (IL-6) inhibitor. IL-6 is an attractive target for the treatment of pJIA. The aim of the study was…
Abstract Number: 0128 • ACR Convergence 2025
Defining a Consensus for Critical Data Fields for International Pediatric Antiphospholipid Syndrome Research
Jheel Bhatt¹, Elizabeth Sloan², Selcan Demir³, Mojca Avramovic⁴, Seza Özen⁵, Doruk Erkan⁶ and Tadej Avcin⁷, ¹Advent Health Orlando, Orlando, FL, ²UT Southwestern, Children's Medical Center, and Scottish Rite for Children, Dallas, TX, ³Eskisehir Osmangazi University, Eskişehir, Turkey, ⁴University Children's Hospital, Ljubljana, Slovenia, ⁵Hacettepe University Medical Faculty, Ankara, Turkey, ⁶Hospital for Special Surgery, New York, NY, ⁷University Children's Hospital University Medical Center Ljubljana, Ljubljana, Slovenia
Background/Purpose: Pediatric antiphospholipid syndrome (APS) is a rare, thrombo-inflammatory autoimmune disease characterized by thrombosis and nonthrombotic manifestations in patients with persistent positive antiphospholipid antibodies, with…
Abstract Number: 2675 • ACR Convergence 2025
RANTES and CXCL10 as Potential Tear-Based Biomarkers Associated with Ocular Damage in Pediatric Chronic Anterior Uveitis
Ilaria Maccora¹, Mariia Pavlenko², Mekibib Altaye³, Hermine Brunner⁴, Alexandra Duell⁴, Megan Quinlan-Waters⁵, Alyssa Sproles⁶, Sherry Thornton⁴, Grant Schulert⁴, Virginia Miraldi Utz⁴ and Sheila Angeles-Han⁶, ¹Rheumatology Unit, ERN ReCoNNET Center, Meyer Children's Hospital IRCCS, Florence, Italy, Firenze, Florence, Italy, ²Rheumatology Division, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA, Cincinnati, OH, ³Cincinnati Children's Hospital, Cincinnati, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Cincinnati Children's Hospital Medical Center, CCHMC, ⁶Cincinnati Children's Hospital, Cincinnati, OH
Background/Purpose: Pediatric chronic anterior uveitis (CAU) leads to sight-threatening complications in approximately 50% of affected children. Among complications, cataract and glaucoma are among the most…
Abstract Number: 2155 • ACR Convergence 2025
A Novel TNFAIP3 Mutation Associated with Large Vessel Vasculitis: Expanding the Phenotypic Spectrum of A20 Haploinsufficiency
Sirada Panupattanapong¹, roshini Abraham², Urekha Karri³, Harry Lesmana¹ and Daniella Schwartz⁴, ¹Cleveland Clinic Foundation, Cleveland, OH, ²Nationwide Children's Hospital, Columbus, OH, ³School of public health, Pittsburgh, PA, ⁴University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Loss-of-function pathogenic variants in TNFAIP3 lead to haploinsufficiency of A20 (HA20), a complex immune dysregulation disorder that can mimic Behcet’s disease, IBD, periodic fever…
Abstract Number: 2131 • ACR Convergence 2025
Transition from Juvenile Dermatomyositis to Spondyloarthritis: A Novel Overlapping Inflammatory Phenotype
Austen Grooms¹, Ioannis Karageorgiou², Kerry Mychaliska² and James Birmingham³, ¹William Beaumont University Hospital, Auburn Hills, MI, ²William Beaumont University Hospital, Royal Oak, MI, ³River City Rheumatology, Grand Rapids, MI
Background/Purpose: Juvenile Dermatomyositis (JDM) is a rare inflammatory disease primarily affecting muscle, skin, and vasculature. Characterized by muscle weakness, distinctive skin lesions, and autoantibodies, it…
Abstract Number: 1816 • ACR Convergence 2025
Single-Cell RNA-Transcriptomics of JDM Skin Identifies JDM-Associated Immune Cell Populations and Dysregulated Interferon Signaling in Immune and Endothelial Cells
Chioma Madubata¹, Jessica Neely², Christine Goudsmit³, Celine Berthier⁴, Zilan Zheng⁵, Sophia Matossian⁴, Jeffrey Dvergsten⁶, Andrew Heaton⁷, J. Michelle Kahlenberg⁴, Gabrielle Fragiadakis⁸ and Jessica Turnier⁹, ¹UCSF, SF, CA, ²UCSF, San Francisco, CA, ³University of Michigan, Ann Arbor, ⁴University of Michigan, Ann Arbor, MI, ⁵University of California, San Francisco, San Francisco, CA, ⁶Duke University Hospital, Hillsborough, NC, ⁷Cure JM Foundation, Anthony, FL, ⁸UCSF, San Francisco, ⁹University of Michigan, Saline, MI
Background/Purpose: Juvenile dermatomyositis (JDM) is the most common idiopathic inflammatory myopathy in children. JDM often presents with rash, and skin inflammation is more refractory to…
Abstract Number: 1673 • ACR Convergence 2025
Is Transient Synovitis of the Hip preclinical Juvenile SpA ? A follow-up study
Anirudh Bandu¹, Michal Cidon² and Michael Weisman³, ¹CHLA, Los Angeles, NJ, ²Children's Hospital of Los Angeles, Los Angeles, CA, ³Cedars-Sinai Medical Center, LOS ANGELES, CA
Background/Purpose: Transient synovitis (TS) of the hip is considered a common, self-limited condition in the pediatric population. However, recurrences can occur; these may signal an…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].